 Clinical Oncology News | Assistant Director Hematology & Stem Cell Transplantation Program Clinical Oncology News The Study Group Indolent Lymphomas (StiL) NHL1 trial demonstrated a progression-free survival (PFS) benefit and improved tolerability with bendamustine and rituximab (B-R) combination when compared with CHOP-R (cyclophosphamide, doxorubicin, ... |
